← Back to Search

Other

10% CBT-006 for Meibomian Gland Dysfunction

Phase 2
Waitlist Available
Research Sponsored by Cloudbreak Therapeutics, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months
Awards & highlights

Study Summary

STUDY DESIGN Structure: Multicenter, randomized, double-masked, vehicle-controlled, parallel group study. Duration: 3 months of TID treatment. Treatment Groups, Dosing, and Treatment Regimen: Study Treatment: CBT-006 topical ophthalmic solution Control Treatment: CBT-006 vehicle

Eligible Conditions
  • Meibomian Gland Dysfunction

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of treatment-emergent adverse events
Secondary outcome measures
Ocular discomfort score (0-4)

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: 2.5% CBT-006Experimental Treatment1 Intervention
Group II: 10% CBT-006Experimental Treatment1 Intervention
Group III: CBT-006Placebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CBT-006
2021
Completed Phase 2
~90

Find a Location

Who is running the clinical trial?

Cloudbreak Therapeutics, LLCLead Sponsor
5 Previous Clinical Trials
926 Total Patients Enrolled
1 Trials studying Meibomian Gland Dysfunction
92 Patients Enrolled for Meibomian Gland Dysfunction

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Safety, Efficacy and Pharmacokinetics of CBT-006 in Patients With Meibomian Gland Dysfunction
2021. "Safety, Efficacy and Pharmacokinetics of CBT-006 in Patients With Meibomian Gland Dysfunction". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04884243.
~25 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top